like us on facebook connect with us on linkedin follow us on twitter December 14, 2022

To learn more about or register for this conferenceCLICK HERE.

Section Header Section Header Section Header

MSHO Featured Corporate Sponsor Assistance Programs

• Puma Patient Lynx
• Rigel OneCare
• Taiho Oncology Patient Support

Details >
Section Header

WPS Oncology Related LCD Updates

December 2022

Stay current on retired and revised policies/articles

Details >

WPS Recent Oncology Related News

Part A, Part B and Part A/B News

• WPS Closures
• Part B Immunosuppressant Drug (Part B-ID) Data in WPS Portal & IVR
• Medicare Hot Links to 2022 Final Rules and the WPS Fee Schedules

Details >
Section Header

CMS-Medicare

Recent Oncology Related Articles

• Dec 2 deadline to Submit a Payment Adjustment Reconsideration
• MIPS SAFER Guide Requirements
• Improper Payments
• Recent Learn Resource & MedLearn Matters Articles
• And more

Details >

Recent RAC Monitor Article

This edition includes articles on

• No Surprise: The NSA Latest FAQ Raises Concern
• Will My Doctor Be a “BOT?”
• Crossing State Lines: The Enigma of Telehealth

Details >
Section Header

BCBSM/BCN

Recent Oncology Related News

• AIM won’t require prior authorization for 29 medical oncology drugs 
• Hemgenix® and Tzield™ to require prior authorization
• And more

Details >

BCBSM/BCN

Publications

• The Record
• BCN Provider News

Details >
Section Header

Current Payer Issue Tracking Page

Last Reviewed/Updated 12/14/22

• 10/11 Update on BCBSM Denials for Auth Exceeds Allowed

Details >

Resolved Payer Issues

Last Reviewed/Updated 12/14/22

• BCBSM Phesgo Issue and Denials for Auth Exceeds Allowed

Details >

Medicaid

Recent Oncology Related News

Medicaid Updates Include
• MSA Bulletin Updates
• Biller "B" Aware Notices

Details >

Newsletters of Interest

• Aetna OfficeLink Updates
• Cigna
• HAP
• Humana YourPractice
• UHC Network News

Details >

Priority Health Update

• Complete D-SNP Model of Care Training by Dec. 31, 2022
• 30-Day Pre-Claim Appeal Deadline
• Medical Policy Updates

Details >
Section Header

Recent Oncology Related FDA Approvals and Expanded Indications

• Rigel Rezlidhia™ (olutasidenib)
• Genentech Tecentriq® (atezolizumab)
• Mirati Krazati™ (adagrasib)

Details >
Section Header Section Header